Recruiting NCT04113486
Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Blood test.
- Who it may be relevant to
- Registry conditions: Carcinoma, Renal Cell. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study aims to observe the difference between NMAP (nicotinamide metabolism associated protein) serum levels in primary diagnosed renal cancer patients and non-renal cancer patient controls, plot the ROC curve and establish appropriate cut-off values.
Interventions
- Other Blood test
About 4 ml of blood draw
Primary outcome measures
- NMAP level study [Time frame: September 2019-September 2021]
Secondary outcome measures (1)
- NMAP plus other tumor biomarkers study [Time frame: September 2019-September 2021]
Eligibility criteria
Inclusion criteria
- The tumor group patients were found to have renal or hepatic mass, plan to receive surgical treatment (except for radiofrequency ablation, cryoablation, etc., which were not available for pathological examination). The control group patients were ruled out of tumor based on radiological tests and commonly used tumor biomarkers
- Age ≥ 18 years old and able to provide written informed consent;
- Have not received any systemic or topical treatment for kidney/liver tumors.
- Cardiopulmonary, liver and kidney functions are able to tolerate surgery and can comply with research requirements.
Exclusion criteria
- The investigators believe that the subject may be unsuitable for inclusion due to severe concurrent diseases, infections, and etc.
- The subjects is known or suspected of other malignancies.
- There has been another history of malignancy in the past 5 years.
- Major surgery (surgery requiring general anesthesia) was performed within 4 weeks prior to screening visits.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Other
Study locations
China · 1 center
- Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine — Shanghai
Identifiers
NCT: NCT04113486 · XHEC-C-2019-104